Rosai–Dorfman Disease with Activating KRAS Mutation — Response to Cobimetinib

A 60-year-old man with fatigue and a perinephric mass was found to have Rosai–Dorfman disease expressing an activating mutation in KRAS. A course of therapy with oral cobimetinib produced a respons...